MRTX News and Press, Mirati Therapeutics Inc. From 10/28/19

Mirati Therapeutics (NASDAQ: MRTX ) is up 22.2% after hours following results from its Phase 1/2 trial of MRTX849 . More news on: Mirati Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Gainers: MRTX   +24.0% . AMKR   +13.3% . TXRH   +9.1% . VRNS   +9.1% . HLIT   +6.1% . More news on: Mirati Therapeutics, Inc., Amkor Technology, Inc., Texas Roadhouse, Inc., Stocks on the move, Read more ...

SAN DIEGO , Oct. 28, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the first clinical results from its Phase 1/2 trial evaluating MRTX849, an investigational KRAS G12C inhibitor, in patients with solid tumors exp...

SAN DIEGO , Oct. 23, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced that the Company will have two presentations at the Society for Immunotherapy of Cancer (SITC) 34 th Annual Meeting on November 6-10, 2019 at the Ga...

Biotech stocks are known for rapid price movements, and on Oct. 28, Mirati Therapeutics (NASDAQ: MRTX) will probably boost the industry's reputation for volatility. That's because the company will finally read out results from a proof-of-concept study with a potential new cancer therapy that...

Noteworthy events during the week of October 20 - 26 for healthcare investors. More news on: Foamix Pharmaceuticals Ltd., Axovant Gene Therapies Ltd., GlaxoSmithKline plc, Healthcare stocks news, , Read more ...

SAN DIEGO , Oct. 17, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present pre-clinical data and initial clinical data on MRTX849, a novel and optimized KRAS G12C inhibitor, in presentations at the AACR-N...

The Society for Immunotherapy of Cancer (SITC) will hold its annual scientific meeting from November 6 to 10 in National Harbor, Maryland. The latest results on promising new cancer therapies that work by harnessing the immune system will be presented. Here we look at three companies that will h...

Every fall, pharmaceutical industry leaders, clinicians, and interested observers of all stripes gather at the annual European Society for Medical Oncology (ESMO) Congress to discuss the latest news in the ongoing attempts to cure various types of cancer. This year, a number of companies unveile...

The European Society for Medical Oncology (ESMO) meeting, which wrapped up on Tuesday, featured presentations from a few smaller companies that saw their stock prices move substantially after the meeting. Data source: YCharts. Seattle Genetics wowed investors with a pair of clinical trials. ...